Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Form 8.5 (EPT/RI)

1 Sep 2011 11:27

RNS Number : 4367N
Bank of America Merrill Lynch
01 September 2011
 



FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING

IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose relevant securities this  Hansen Transmissions International NV

form relates:

(c) Name of the party to the offer with which exempt Advisor to Hansen Transmissions International NV

principal trader is connected:

(d) Date dealing undertaken: 31/08/2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the NO

Code in respect of any other party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - BE0947727377 Purchase 11,884 GBP 0.64 GBP 0.64

Common - BE0947727377 Sale 18,730 GBP 0.65 GBP 0.64

(b) Derivatives transactions (other than options)

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - BE0947727377 Swap SHORT 8549 GBP 0.64

Common - BE0947727377 Swap SHORT 2081 GBP 0.64

Common - BE0947727377 Swap SHORT 529 GBP 0.64

Common - BE0947727377 Swap SHORT 439 GBP 0.64

Common - BE0947727377 Swap SHORT 286 GBP 0.64

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - BE0947727377 Swap LONG 2637 GBP 0.64

Common - BE0947727377 Swap LONG 16093 GBP 0.64

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant security Product description Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing Details Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 01/09/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

 

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING

IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose relevant securities this INVESTEC PLC

form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and INVESTEC LTD

principal trader is connected:

(d) Date dealing undertaken: 31/08/2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the NO

Code in respect of any other party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB00B17BBQ50 Purchase 53,695 GBP 48.76 GBP 4.28

Common - GB00B17BBQ50 Sale 55,357 GBP 49.49 GBP 4.20

(b) Derivatives transactions (other than options)

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - GB00B17BBQ50 Swap SHORT 252 GBP 4.25

Common - GB00B17BBQ50 Swap SHORT 78 GBP 4.29

Common - GB00B17BBQ50 Swap SHORT 30870 GBP 4.28

Common - GB00B17BBQ50 Swap SHORT 2896 GBP 4.28

Common - GB00B17BBQ50 Swap SHORT 2000 GBP 4.29

Common - GB00B17BBQ50 Swap SHORT 719 GBP 4.28

Common - GB00B17BBQ50 Swap SHORT 9679 GBP 4.29

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - GB00B17BBQ50 Swap LONG 800 GBP 4.19

Common - GB00B17BBQ50 Swap LONG 6758 GBP 4.32

Common - GB00B17BBQ50 Swap LONG 246314 GBP 0.00

Common - GB00B17BBQ50 Swap LONG 64659 GBP 0.00

Common - GB00B17BBQ50 Swap LONG 30870 GBP 0.00

Common - GB00B17BBQ50 Swap LONG 3025 GBP 0.00

Common - GB00B17BBQ50 Swap LONG 844 GBP 4.19

Common - GB00B17BBQ50 Swap LONG 252 GBP 2.27

Common - GB00B17BBQ50 Swap LONG 259 GBP 4.19

Common - GB00B17BBQ50 Swap LONG 138 GBP 4.23

Common - GB00B17BBQ50 Swap LONG 132 GBP 0.00

Common - GB00B17BBQ50 Swap LONG 14 GBP 4.21

Common - GB00B17BBQ50 Swap LONG 33514 GBP 4.27

Common - GB00B17BBQ50 Swap LONG 719 GBP 4.27

Common - GB00B17BBQ50 Swap LONG 2896 GBP 4.26

Common - GB00B17BBQ50 Swap LONG 600 GBP 4.29

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant security Product description Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing Details Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 01/09/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

 

 

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING

IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose relevant securities this Evolution Group Plc

form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and INVESTEC LTD

principal trader is connected:

(d) Date dealing undertaken: 31/08/2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the NO

Code in respect of any other party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB0030221864 Purchase 2,288 GBP 0.92 GBP 0.92

(b) Derivatives transactions (other than options)

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - GB0030221864 Swap SHORT 1693 GBP 0.92

Common - GB0030221864 Swap SHORT 595 GBP 0.92

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant security Product description Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing Details Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 01/09/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING

IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose relevant securities this Autonomy Corporation Plc

form relates:

(c) Name of the party to the offer with which exempt Advisor to Autonomy Corporation Plc

principal trader is connected:

(d) Date dealing undertaken: 31/08/2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the NO

Code in respect of any other party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB0055007982 Purchase 108,803 GBP 25.20 GBP 25.13

Common - GB0055007982 Sale 95,689 GBP 25.20 GBP 25.13

(b) Derivatives transactions (other than options)

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - GB0055007982 Swap SHORT 8913 GBP 25.18

Common - GB0055007982 Swap SHORT 5674 GBP 25.17

Common - GB0055007982 Swap SHORT 3450 GBP 25.18

Common - GB0055007982 Swap SHORT 388 GBP 25.15

Common - GB0055007982 Swap SHORT 337 GBP 25.17

Common - GB0055007982 Swap SHORT 307 GBP 25.13

Common - GB0055007982 Swap SHORT 276 GBP 25.13

Class of Product description   Nature of dealing Number of reference   Price per unit

relevant eg. CFD securities

security

Common - GB0055007982 Swap LONG 243 GBP 25.19

Common - GB0055007982 Swap LONG 388 GBP 25.20

Common - GB0055007982 Swap LONG 565 GBP 25.19

Common - GB0055007982 Swap LONG 628 GBP 25.19

Common - GB0055007982 Swap LONG 779 GBP 25.13

Common - GB0055007982 Swap LONG 1478 GBP 25.15

Common - GB0055007982 Swap LONG 2465 GBP 25.18

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant security Product description Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing Details Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 01/09/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBFLFBFKFLBBE
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.